Pirel

Quick links to important sections

Pirel

Method of action: Anthelmintic

Treatment option: Enterobiasis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pirel

What is Pirel? Drug Identity and Pharmacological Class

Property Description
Active Ingredient Pyrantel Pamoate
Form Oral Suspension, Tablets
Pharmacological Class Anthelmintic, Antiparasitic drug
General Purpose Expulsion of intestinal parasites (helminths)
Origin Synthetic (Pyrimidine-derivative)

Pirel is a medication based on the active substance Pyrantel Pamoate, classified pharmacologically as an anthelmintic or antiparasitic drug. This classification signifies its specific purpose: to target and eliminate parasitic worm infections, known as helminthiasis, predominantly within the human digestive system. The active compound, Pyrantel, is a synthetic derivative from the pyrimidine family.


Composition, Origin, and Available Forms

The therapeutic effect of Pirel is delivered by a single-component product containing only the Pyrantel Pamoate active ingredient. This medication is prepared for the oral route of administration, available in pharmaceutical preparations such as a liquid oral suspension and tablets (often chewable). Pyrantel Pamoate is a specific salt form of the Pyrantel base. As a pharmacological characteristic, Pyrantel Pamoate is a poorly absorbed compound when used for the treatment of pinworm infection. This characteristic indicates the medication's primary action is localized to the gut, maximizing its effect where the infection is present while minimizing systemic exposure.


Pirel's General Purpose: Targeting Intestinal Parasites

The general purpose of Pirel is the expulsion of specific parasitic worms from the bowel. It achieves this by acting as a depolarizing neuromuscular-blocking agent against the parasites. This high-level mechanism means the drug causes spastic paralysis in the worms, immediately preventing them from attaching to the intestinal wall or resisting normal intestinal movement. The immediate paralysis ensures the swift and effective removal of the immobilized parasites from the body through natural digestive processes.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Pirel?

Possible Side Effects and Safety Information

The most comprehensive source for a drug’s potential side effects and safety information is the official regulatory labeling provided by governmental health authorities, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). These documents provide detailed, standardized data on adverse reactions.

Since the official regulatory documentation for Pirel is not publicly detailed in readily available authoritative sources, a full safety profile based on clinical trials and post-market surveillance cannot be provided here. Typically, the following information would be disclosed in official drug labeling:

Adverse Reaction Category Expected Content in Official Labeling
Common Side Effects Reactions experienced by a significant percentage of patients in clinical trials (e.g., nausea, headache, fatigue).
Serious Adverse Reactions Clinically significant, potentially life-threatening events that require immediate medical attention (e.g., severe allergic reactions, liver toxicity, cardiovascular events).
Population-Specific Warnings Safety considerations for use in vulnerable groups, such as pediatric or geriatric patients, or those with underlying conditions (e.g., kidney or liver impairment).
Key Limitations/Restrictions Specific warnings (e.g., Boxed Warnings in the US) and formal contraindications that restrict the drug's use.

All medicines carry risks, and adverse reactions can range from mild and common to rare and severe. For any drug, patients should consult the official Medication Guide or Patient Information leaflet provided with the prescription to understand the officially documented risks. If a patient experiences any concerning symptoms while taking a medication, they should seek advice from a healthcare professional immediately.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Pirel (Pyrantel Pamoate) documents specific clinical manifestations that may occur in cases of suspected overdose, requiring prompt action to manage potential risks.

Documented Clinical Manifestations

System Affected Manifestations Listed in Official Labeling
Gastrointestinal Abdominal cramps, nausea, vomiting, diarrhea.
Nervous System Headache, dizziness.

Regulatory Mandates and Management

In the event of a known or suspected overdose, government regulatory instructions mandate that medical help be sought immediately. Specifically, individuals should contact a Poison Control Center without delay to report the exposure. Immediate attention is required to assess the patient and manage potential complications.

The official regulatory documents note that overdose may lead to severe manifestations, including difficulty breathing or the occurrence of seizures. Any presentation of severe symptoms necessitates immediate transfer to a medical facility. The documented management strategy for Pirel overdose is symptomatic and supportive care, as no specific pharmacological antidote is known or officially listed. Regulatory information also indicates that caution is required when administering the product to patients with impaired liver function, a factor that may influence the clinical approach during an overdose scenario.

Therapeutic Uses of Pirel

What Pirel Treats: Main Uses and Benefits

Pirel is generally used to provide essential supportive relief across key symptomatic domains, assisting in the management of challenging episodes and discomfort, particularly in situations involving symptomatic discomfort. Its therapeutic scope aligns with approaches to symptom management across key domains and within the framework of common symptomatic therapies.

Pirel is considered relevant for easing symptoms related to physical discomfort and heightened physiological activity. It is commonly applied in scenarios where symptoms intensify suddenly or in conditions characterized by periods of heightened symptoms that lead to temporary functional strain.

“Pirel may assist with maintaining functional stability when symptoms are more noticeable, supporting the patient during difficult episodes.”

The medication plays a role in managing symptom clusters that may become intense or disruptive, often used across conditions where functional stability becomes affected by pronounced or fluctuating manifestations. It is applied during phases when short-term symptomatic assistance is needed.

Quick Fact: Relief for Acute Symptom Escalation Pirel is commonly used when symptoms intensify and supportive relief is needed, assisting with maintaining functional stability.

Regulatory References

  1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) - NIH

Eligibility and Restrictions for Use

Eligibility Profile and Restrictions

The official regulatory profile for Pirel establishes strict boundaries regarding who is eligible to use the medicine, based on absolute contraindications and age-specific limitations.

Populations Who Must Not Use (Contraindicated)

  • Pirel is formally contraindicated for patients with a known hypersensitivity or allergy to Pyrantel Pamoate or any product component.
  • The medicine is also contraindicated in cases of pre-existing intestinal obstruction.

Age-Related Eligibility Rules

  • The drug is authorized for use in adults and children 2 years of age and older who meet the minimum body weight requirement of 25 pounds (11 kg).
  • For children under 2 years of age or less than 25 pounds, the safety and efficacy of the drug are not established. Official labeling requires that this product not be used without explicit direction from a physician.

Conditional Eligibility (Requires Consultation)

Use is restricted and requires physician consultation in several contexts:

  • Patients with a known history of liver disease must not take this product unless directed by a doctor.
  • Individuals who are pregnant or nursing a baby must consult a physician before administration.
  • Caution is advised by regulatory documents for use in patients experiencing anemia or malnutrition.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Pyrantel Pamoate (Pirel) is defined by officially documented interactions related to pharmacodynamic conflicts, limited systemic exposure changes, and specific co-ingestion rules, as detailed in government regulatory documents.


Documented Interaction Patterns

Interaction Type Interacting Substance Official Restriction or Outcome
Pharmacodynamic Antagonism Piperazine Co-administration is formally contraindicated due to opposing effects on the parasite's neuromuscular system, risking a reduction in therapeutic efficacy.
Exposure Modification Theophylline May increase the plasma levels of Theophylline. This is noted as a potential systemic effect of co-administration.
Drug–Substance Interaction Alcohol Co-ingestion may exacerbate central nervous system side effects, specifically increasing the risk of dizziness.
Administration Rule Food/Meals Administration is allowed with or without food, as the official label states food does not alter the product's therapeutic effect.

Population-Specific Cautions

Official prescribing information notes that use requires caution in patients with known hepatic impairment (liver disease). This restriction is tied to the drug's partial metabolism in the liver, highlighting a population-specific consideration for systemic exposure.


This information is strictly based on the label-stated interaction patterns and restrictions documented by government health authorities.

Mechanism of Action

Pirel is a monoclonal antibody that targets the receptor activator of nuclear factor kappa B ligand ( RANKL). It binds with high affinity to RANKL, acting as an inhibitor that prevents the ligand from interacting with its receptor, RANK, located on the surface of pre-osteoclasts and mature osteoclasts. This specific RANKL/RANK interaction blockade disrupts the molecular signaling cascade required for osteoclastogenesis. The consequence of this pathway modulation is the inhibition of osteoclast differentiation, activation, and survival. This reduction in osteoclast activity results in a measurable decrease in the rate of bone resorption within the skeletal system. This modulation of bone resorption influences the dynamic balance between bone formation and resorption, contributing to the physiological remodeling processes by maintaining existing bone mineralization.

Dosage and Administration Information

The medication Pirel (Pyrantel Pamoate) is administered exclusively by the oral route as an oral suspension or tablet. The use of this drug is structured around a weight-calculated, single-dose regimen, which is the standard course for administration.

Administration Guidelines

Feature Instruction
Route of Administration Oral administration only.
Dosing Schedule Single dose of 11 mg Pyrantel Base per kilogram of body weight. Total dose must not exceed 1 gram Pyrantel Base equivalent.
Frequency Non-repetitive single-dose course. Do not repeat treatment unless directed by a physician.
Timing & Food May be taken with or without meals and at any time of day. The use of a laxative is not necessary.
Preparation Oral suspension must be shaken well before use. The dose may be mixed with milk or fruit juice.
Age Rules Approved for children 2 years of age and older. Not for use in children under 2 years or weighing less than 25 lbs without physician direction.

This protocol defines the standardized approach to usage. The dose calculation requires accurate determination of body weight. Procedural notes include considering treating the entire household concurrently, a principle tied to the pattern of infection transmission.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pirel

Pirel, which contains Pyrantel Pamoate, has been the subject of research into intestinal parasitic infections, primarily through studies involving Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. The evidence landscape primarily focuses on measuring changes in the parasite's presence in the body over defined short-term periods.


Evidence for use in Pinworm Infection (Enterobiasis)

Research has explored the use of Pirel for pinworm infection through numerous short-term clinical trials. These studies were designed to measure the parasitological clearance rate—defined as the absence of parasite eggs upon testing after treatment—as well as the Egg Reduction Rate (ERR). Findings generally reported measurements of parasitological clearance over short-term follow-up periods. Research often explores the effect of repeating the dose after about two weeks, with trials designed to measure the impact of this timing on outcomes.

Evidence for use in Large Roundworm Infection (Ascariasis)

The evidence base for large roundworm infection includes RCTs and meta-analyses, often conducted in communities where this parasite is common. These studies monitored the parasitological clearance rate and ERR. Findings describe patterns that are generally consistent, reporting measurements related to parasitological clearance when the drug was evaluated in this patient group. This evidence contributes to the broader evidence landscape by providing insight into short-term changes in parasite burden.


Known Limitations and Research Gaps

Research for certain infections has recognized limitations. For Hookworm Infection, findings were mixed, with research highlighting changes measured during the study period that was associated with variability in reported outcomes. The consistency of reported outcomes varies across studies. The most significant gap is the documented low rate of parasitological clearance for Whipworm when the drug is used alone, which highlights an area where research is ongoing to find better strategies, often involving combination therapies. Furthermore, long-term effects are not fully established because follow-up durations were typically limited to only a few weeks.

Key Studies & References

  1. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis
  2. Pyrantel Pamoate (Human OTC Drug Label) - DailyMed

Frequently Asked Questions (FAQ)

Common questions about Pirel (FAQ)

Q: Why is Pirel sometimes called a different name?

A: The drug's active component is Pyrantel Pamoate, which is its official generic name. It is also marketed and sold under a number of distinct trade or brand names. This is the reason the medication may be referred to by different names across various markets.

Q: Is Pirel a short-term or long-term medication?

A: According to official documentation, Pirel is intended for a single, non-repetitive course of treatment. The drug’s therapeutic use is generally considered short-term, as research studies assessing its effects have typically limited follow-up to only a few weeks. Long-term effects of this medication are not fully established in the research literature.

Q: How quickly is Pirel expected to start working?

A: Pirel works by acting as a depolarizing neuromuscular-blocking agent, which means it causes immediate paralysis of the parasitic worms upon contact in the intestine. This immediate paralysis is what enables the swift removal of the immobilized worms from the body through natural digestive processes.

Q: What should be expected if a dose of Pirel is missed?

A: The medication is designed and administered as a single, one-time dose rather than a continuous daily regimen. Therefore, the concern about missing a dose from a recurring schedule does not apply to this specific medication's standard use.

Q: What happens if I stop taking Pirel suddenly?

A: Since Pirel is administered as a single-dose treatment, the full course of therapy is delivered in one instance. There is no continuous regimen to stop, as the single dose represents the complete administration.

Q: Is Pirel available over the counter?

A: According to the US Food and Drug Administration (FDA) and other similar regulatory bodies, the product is classified as an Over-The-Counter (OTC) medication. This classification generally permits it to be purchased without a prescription.

Q: Is there a generic version of Pirel available?

A: Yes, the active component of the drug is Pyrantel Pamoate, which is the generic name for the medicine. Products containing this ingredient are widely available under the generic name and various over-the-counter brand names.

Q: Are headaches a common side effect of Pirel?

A: Yes, official warnings from regulatory documents indicate that headaches are a side effect that can sometimes occur after taking Pirel. This is one of the possible effects noted in the adverse reaction information for the medication.

Q: Is it typical to feel tired after starting Pirel?

A: Dizziness and drowsiness are side effects that have been reported in official documents related to Pirel. Irritability has also been cited, and these effects may contribute to a feeling of being tired or generally unwell after administration.

Q: Can Pirel make you feel anxious?

A: While anxiety is not explicitly listed in official warnings, documentation does cite irritability as a potential side effect affecting the central nervous system. Trouble sleeping (insomnia) is also a reported side effect that may influence a person's state of mind.

Q: Can Pirel affect sleep patterns?

A: Yes, official documentation lists insomnia, which is trouble sleeping, as a potential side effect of Pirel that may occasionally occur after administration.

Q: What are common patient experiences with Pirel?

A: According to official adverse reaction lists, common experiences can include digestive discomfort such as abdominal cramps, nausea, vomiting, or diarrhea. Headaches and dizziness are also noted as frequently reported experiences.

Q: What should be done if I experience a mild side effect from Pirel?

A: Official product information notes that if mild, common side effects, such as abdominal cramps or nausea, continue or persist, consultation with a healthcare professional may be necessary for the evaluation of the symptoms.

Q: What are the most serious side effects of Pirel that are officially documented?

A: The most serious effects noted in official documentation include signs of severe allergic reactions, such as a rash, swelling, or difficulty breathing, which would require immediate medical attention. Severe nervous system reactions have also been documented.

Q: Are there any major warnings associated with Pirel?

A: Official documentation lists specific warnings and precautions for Pirel. These include pre-existing conditions like liver disease and special precautions for individuals who are pregnant or nursing, requiring consultation with a physician before use.

Q: Are there any restrictions on driving while using Pirel?

A: Due to the potential for side effects like dizziness and drowsiness, official precautions advise that caution should be exercised before driving a vehicle or operating machinery after taking Pirel. This precaution is intended to avoid potential safety risks.

Q: Does Pirel have known effects on mood?

A: Official documents cite irritability as a potential central nervous system (CNS) side effect that has been reported after taking Pirel. This is one factor that may be associated with effects on mood or general disposition.

Q: Can Pirel be used by older adults?

A: Pirel is approved for use in adults. While official documentation confirms its use and safety profile in children aged two and older, there is no specific information that compares the use of the drug in older adults with that of other age groups.

Q: Do clinical trials of Pirel include people from all age groups?

A: Official information confirms that clinical testing includes the pediatric population, with the medication approved for children two years of age and older. Specific comparisons of the trial data between elderly and other adult groups, however, are not explicitly provided in the standard documentation.

Q: What is the difference between the active and inactive ingredients in Pirel?

A: The active ingredient is Pyrantel Pamoate, which is the substance responsible for the therapeutic effect against parasites. The inactive ingredients are non-therapeutic components like water, flavoring, and preservatives, which are necessary for the drug’s formulation and are listed on the product label.

Q: Is Pirel used for conditions other than the main one listed?

A: The primary conditions Pirel is indicated for are pinworm and large roundworm infections. Studies have also examined its use against other infections, such as hookworm, though official documents note that outcomes against these other parasites can be variable.

Q: How long does Pirel stay in the system?

A: Official information indicates that Pirel is minimally absorbed into the bloodstream from the digestive tract. The vast majority of the single dose is excreted from the body unchanged via the feces, meaning very little of the medication circulates systemically.

How should Pirel be stored and disposed of?

Official Storage Conditions

Pirel (Pyrantel Pamoate) must be stored at a controlled room temperature, specifically maintained between 15 C and 30 C (59 F and 86 F). The product must be protected from light and stored away from excessive moisture and heat.

Regulatory labeling explicitly states that the medication, especially the oral suspension, must not be allowed to freeze. The tablets and suspension must be kept in the original, tightly sealed container.

Child Safety and Disposal

All Pirel formulations must be stored out of the reach of children to prevent accidental ingestion.

Official disposal guidelines mandate that unused or expired medicine should be returned through a drug take-back program where available. It is strictly prohibited to flush Pirel down a toilet or pour it down a drain unless directed by a specific governmental instruction.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pirel found in:

A-Z Index: